PLoS ONE · 2011 · 27 citations · 33 references
Life SciencesCell BiologyOncologyInflammationMolecular OncologyTumor ImmunologyCytokine BiologyCytokine RegulationCytokine SignalingInflammatory SignalingKidney CancerRenal Cell CarcinomaCytokine InhibitionCytokine Signaling In CancerCytokine Signaling In TumorsFlow Cytometric AnalysisFlow Cytometric Cell AnalysisGrowth Inhibition AssaysHost Defense ModulationTumor-associated Cytokines
BACKGROUND: Renal cell carcinoma (RCC) is one of the most common kidney cancers and is highly resistant to chemotherapy. Accumulating evidence suggests that interleukin-22 (IL-22) may mediate host defense against varietal pathogens as a proinflammatory and anti-inflammatory cytokine. The purpose of this study is to assess the inhibitory effects of IL-22 on human RCC cell line A498 and to investigate the possible mechanisms underlying the anti-tumor effects of this cytokine. METHODOLOGY: A498 cells, a RCC cell line, were used to assess the inhibitory growth effects of IL-22 using the MTT assay and flow cytometric analysis in vitro. BALB/C nude mice bearing A498 cell xenografts were used to examine the antitumor efficacy of IL-22 in vivo. Western blotting assay was performed to detect the regulation of the intracellular signaling pathway of IL-22. PRINCIPAL FINDINGS: We found that IL-22 suppressed the growth of A498 cells in a dose-dependent manner and inhibited the growth of A498 xenografts. We also observed that IL-22 produced a dose-dependent inhibitory effect on A498 cells that involved the induction of G2/M cell cycle arrest without cell apoptosis. Moreover, we showed that the phosphorylation of STAT1 was increased and the phosphorylation of ERK1/2 was attenuated in A498 cells exposed to IL-22. The growth inhibition of A498 cells was partially revised after IL-22 treatment as the expression of STAT1 was knocked down. And inflammatory cytokines, interferon-α and tumor necrosis factor-α (TNF-α) were barely involved in the suppression of A498 cell xenografts treated with IL-22. CONCLUSIONS: IL-22 dose-dependently suppresses RCC cell line A498 cells in vitro and induces growth inhibition of A498 cell-bearing mouse xenografts. These results suggest that the anti-RCC effects of IL-22 are at least partially mediated through regulation of STAT1 signaling pathways and G2/M cell cycle arrest, rather than by inducing apoptosis and inflammatory cytokines.
33
IL-22 Increases the Innate Immunity of Tissues
Kerstin Wolk, Stefanie Kunz, Ellen Witte et al. · Immunity · 2004 · 1.3K citations · Full text
Life Sciences, Immunology, Pathology +12
THE CHANGING NATURAL HISTORY OF RENAL CELL CARCINOMA
Allan J. Pantuck, Amnon Zisman, Arie S. Belldegrun · The Journal of Urology · 2001 · 842 citations
Medicine, Cancer Biology, Oncology +10